Sign in →

Test Code C6FX C6 Complement, Functional, Serum

Reporting Name

C6 Complement, Functional, S

Useful For

Diagnosis of C6 deficiency

 

Investigation of a patient with an undetectable total complement level

Method Name

Automated Liposome Lysis Assay

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum Red


Ordering Guidance


The total complement assay (COM / Complement, Total, Serum) should be used as a screen for suspected complement deficiencies before ordering individual complement component assays. A deficiency of an individual component of the complement cascade will result in an undetectable total complement level.

Specimen Required


Patient Preparation: Fasting preferred

Supplies: Sarstedt 5 mL Aliquot Tube (T914)

Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Immediately after specimen collection, place the tube on wet ice.

2. Centrifuge and aliquot serum into plastic vial.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Frozen 14 days

Reject Due To

Gross hemolysis OK
Gross lipemia Reject
Gross icterus OK

Reference Values

32-57 U/mL

Day(s) Performed

Monday through Friday

CPT Code Information

86161

LOINC Code Information

Test ID Test Order Name Order LOINC Value
C6FX C6 Complement, Functional, S 60459-5

 

Result ID Test Result Name Result LOINC Value
C6FX C6 Complement, Functional, S 60459-5

Clinical Information

Complement proteins are components of the innate immune system. There are 3 pathways to complement activation: 1) the classical pathway, 2) the alternative (or properdin) pathway, and 3) the lectin (mannan-binding lectin) pathway. The classical pathway of the complement system is composed of a series of proteins that are activated in response to the presence of immune complexes. A single IgM molecule or 2 IgG molecules are sufficient to trigger activation of the recognition complex initiated by C1q. The activation process triggers a cascade that includes an amplification loop. The amplification loop is mediated by C3, with cleavage of a series of proteins, and results in 3 main end products: 1) anaphylatoxins that promote inflammation (C3a, C5a), 2) opsonization peptides that are chemotactic for neutrophils (C3b) and facilitate phagocytosis, and 3) the membrane attack complex (MAC), which promotes cell lysis.

 

Patients with deficiencies of the late complement proteins (C5, C6, C7, C8, and C9) are unable to form the MAC, and may have increased susceptibility to neisserial infections.

 

C6 deficiency is relatively rare, over 50 cases have been described. Most of these patients have systemic meningococcal infection and some have had invasive gonococcal infections. Normal levels of C6 antigen have been reported in patients with dysfunctional C6 lytic activity, hence the recommendation of functional testing.

Interpretation

Low levels of complement may be due to inherited deficiencies, acquired deficiencies, or due to complement consumption (eg, as a consequence of infectious or autoimmune processes). Absent C6 levels in the presence of normal C3 and C4 values are consistent with a C6 deficiency. Absent C6 levels in the presence of low C3 and C4 values suggests complement consumption.

 

Normal results indicate both normal C6 protein levels and normal functional activity.

Cautions

Absent (or low) C6 functional levels in the presence of normal C6 antigen levels should be replicated with a new serum specimen to confirm that C6 inactivation did not occur during shipping.

Method Description

C6 complement activity is measured by mixing patient serum with a C6-deficient serum. The lytic activity of the serum mixture is tested against sensitized, labeled liposomes. If lysis occurs, the patient serum must be the source of the C6. The target liposomes are a commercial reagent (WAKO total complement CH50), and the assay is performed on an Advia XPT.(Unpublished Mayo method)

Report Available

1 to 3 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.